Unlike typical drugs with inelastic demand, the market for GLP-1s is price-elastic. Eli Lilly's CEO confirms that lowering prices directly expands the user base, creating a rare instance where capitalist incentives align with broader consumer access in the pharmaceutical industry.

The combined annual revenue of just two GLP-1 peptides, semaglutide and tirzepatide, is projected to exceed $55 billion. This figure nearly rivals the revenue of the entire AI large language model industry, demonstrating the massive, often underestimated, economic scale of the market for effective metabolic health solutions.

The GLP-1 market is projected to face intense competition from both generics (like statins) and high-rebate branded drugs (like ED medications). This dual pressure will squeeze profit margins, drive net prices down significantly, and ultimately compel broad payer coverage due to the drugs' strong clinical return on investment.

Companies like Amgen and AstraZeneca are entering the obesity market by addressing the pitfalls of current GLP-1s. Instead of trying to beat market leaders on pure efficacy, they are focusing on improved tolerability, dosing convenience, and targeted benefits like visceral fat loss to carve out a niche.

The surge in use of compounded GLP-1s, costing about half the price of branded versions, demonstrates huge untapped demand. Patients are willing to accept manufacturing and safety risks for affordability, proving price is a major barrier to adoption.

The metabolic disease market is seeing intense innovation beyond standard injectables. Structure Therapeutics' oral GLP-1 agonist showed efficacy comparable to injections in Phase 2, while Novo Nordisk's triple agonist demonstrated superior results to semaglutide, signaling a multi-pronged assault on current market leaders.

Tirzepatide is a rare "once in a blue moon" drug because it is both more potent and better tolerated than its main competitor. This paradoxical profile—achieving superior efficacy with fewer side effects—has established it as the "king of the hill" in the obesity market and created an extremely high bar for any challenger.

As the obesity market matures, the key differentiator may shift from maximum weight loss to tolerability. High discontinuation rates for GLP-1s due to GI side effects create an opportunity for drugs with slightly lower efficacy but a stellar safety profile, which could capture a large and underserved patient segment.

The introduction of low-cost generic semaglutide in India revealed massive pent-up demand. Volumes surged sixfold in just two months, driving such significant market expansion that the total market value is projected to grow eightfold by 2030, even with lower per-unit prices.